PLC Systems to Host First Quarter Conference Call on May 15, 2008
05 Mai 2008 - 3:18PM
PR Newswire (US)
FRANKLIN, Mass., May 5 /PRNewswire-FirstCall/ -- PLC Systems Inc.
(AMEX:PLC) announced today that it expects to release to the news
wire its financial results for the first quarter ended March 31,
2008 before the market opens on Thursday, May 15, 2008. The company
plans to host a conference call to discuss those results at 11:00
a.m. ET on that same day. The call may be joined via telephone by
dialing (800) 638-4930 or (617) 614-3944 (for international
participants) at least five minutes prior to the start of the call.
The conference ID code is: 63587177. A live webcast of the
conference call will be available by visiting the PLC Systems
website, http://www.plcmed.com/ five minutes before the call
begins. The webcast will be archived on this site starting one hour
after the call is completed. In addition, a telephonic replay of
the call will be available beginning at 1:00 p.m. ET on May 15,
2008, through midnight on May 22, 2008, and can be accessed by
dialing (888) 286-8010 or (617) 801-6888 (for international
participants), using conference ID code 30142513. About PLC Systems
Inc. PLC Systems Inc. is a medical technology company specializing
in innovative technologies for the cardiac and vascular markets.
Headquartered in Franklin, Mass., PLC pioneered the CO2 Heart Laser
System, which cardiac surgeons use to perform CO2 transmyocardial
revascularization (TMR) to alleviate symptoms of severe angina. CO2
TMR offers a treatment option for angina patients who suffer from
severe coronary artery disease. The CO2 Heart Laser is the world's
first TMR angina relief device cleared for commercial distribution
by both the U.S. Food and Drug Administration and Japanese Ministry
of Health, Labor and Welfare, and to obtain a CE Mark for European
distribution. The company completed a pilot clinical safety study
of its RenalGuard Therapy(TM) and RenalGuard System(TM) and has
received its CE Mark Certificate for RenalGuard System. PLC
recently received FDA conditional approval to commence a U.S.
pivotal trial to study the effectiveness of its RenalGuard Therapy
and RenalGuard System in the prevention of Contrast-Induced
Nephropathy (CIN). RenalGuard Therapy is designed to reduce the
toxic effects that contrast media can have on the kidneys. This
therapy is based on the theory that creating and maintaining a high
urine output is beneficial to patients undergoing imaging
procedures where contrast agents are used. The real-time
measurement and matched fluid replacement design of the RenalGuard
System is intended to ensure that a high urine flow is maintained
before, during and after these procedures. This should allow the
body to rapidly eliminate contrast, reducing its toxic effects. The
RenalGuard System, with its matched fluid replacement capability,
is intended to minimize the risk of over- or under-hydration.
Additional company information can be found at
http://www.plcmed.com/. PLC Systems, PLC Medical Systems, PLC, CO2
Heart Laser, RenalGuard, RenalGuard System and RenalGuard Therapy
are trademarks of PLC Systems Inc. Contact: Mary T. Conway Conway
Communications 617-244-9682 DATASOURCE: PLC Systems Inc. CONTACT:
Mary T. Conway of Conway Communications for PLC Systems Inc.,
+1-617-244-9682, Web site: http://www.plcmed.com/
Copyright
P L C Systems (AMEX:PLC)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
P L C Systems (AMEX:PLC)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über Plc Systems, (Amerikanische Börse): 0 Nachrichtenartikel
Weitere Plc Systems, News-Artikel